Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix is favorably positioned because the LUCIA trial miss and Duravyu discontinuation remove its most relevant TKI implant competitor, leaving Axpaxli in the pole position for wAMD among TKI inserts. Axpaxli has a differentiated profile with potential 9-12 month dosing intervals, supported by phase 3 SOL-1 results and interim SOL-R safety data, with an NDA filing expected in 4Q26. Even as Zenkuda showed competitive phase 3 DAYBREAK data and ~50% of patients received 6-month injections, Axpaxli’s longer durability and possible superiority claims versus Eylea could improve access and reimbursement in a crowded anti-VEGF market.

Ocular Therapeutix is viewed negatively because its investment case is heavily dependent on Axpaxli, a Phase 3 asset that still faces meaningful FDA, efficacy, and safety uncertainty, while the company’s current revenue-generating product, Dextenza, is not enough to offset pipeline risk. Even with positive Phase 3 SOL-1 data, approval remains subject to the adequacy of the NDA package, and the text highlights that Ocular has incurred significant losses since inception, underscoring its reliance on substantial future funding. Commercially, Axpaxli would enter a crowded anti-VEGF market against larger competitors, and reimbursement, physician adoption, and escalating development costs could pressure returns if clinical or regulatory milestones disappoint.